Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SARILUMAB Cause Maternal exposure timing unspecified? 110 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 110 reports of Maternal exposure timing unspecified have been filed in association with SARILUMAB (KEVZARA). This represents 0.5% of all adverse event reports for SARILUMAB.

110
Reports of Maternal exposure timing unspecified with SARILUMAB
0.5%
of all SARILUMAB reports
94
Deaths
104
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From SARILUMAB?

Of the 110 reports, 94 (85.5%) resulted in death, 104 (94.5%) required hospitalization, and 102 (92.7%) were considered life-threatening.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SARILUMAB. However, 110 reports have been filed with the FAERS database.

What Other Side Effects Does SARILUMAB Cause?

Drug ineffective (5,065) Pain (4,833) Arthralgia (4,139) Rheumatoid arthritis (3,963) Joint swelling (3,951) Condition aggravated (3,247) Fatigue (3,000) Rash (2,912) Alopecia (2,660) Abdominal discomfort (2,600)

What Other Drugs Cause Maternal exposure timing unspecified?

RITUXIMAB (402) METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) SECUKINUMAB (301)

Which SARILUMAB Alternatives Have Lower Maternal exposure timing unspecified Risk?

SARILUMAB vs SATRALIZUMAB SARILUMAB vs SATRALIZUMAB-MWGE SARILUMAB vs SAXAGLIPTIN SARILUMAB vs SCHOLL'S INGROWN TOENAIL PAIN RELIEVER SARILUMAB vs SCOPOLAMINE

Related Pages

SARILUMAB Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified SARILUMAB Demographics